Benign Prostatic Hyperplasia Treatment Segmentation
Treatment Type (Drug Treatment, Surgical Treatment)
The drug treatment segment in benign prostatic hyperplasia treatment market is projected to witness noteworthy growth over the forecast period. The growth of the drug treatment segment is attributed to the rising consumption of drugs across the world. Furthermore, with companies receiving FDA approvals for the treatment of the disease also boosts the market growth significantly. In May 2024, Sumitomo Pharma America, Inc. received U.S. FDA approval for its vibegron (GEMTESA), a beta-3 adrenergic receptor (β3) agonist, supplemental New Drug Application (sNDA), for treating men with overactive bladder symptoms receiving pharmacological therapy for benign prostatic hyperplasia (BPH).
Therapeutic Class (BPH Devices, Transurethral RF Thermal Therapy, Suture Base Implant, Others, BPH Drugs, Alpha Blocker, Muscarinic Receptor Antagonist, 5-Alpha Reductase Inhibitors)
The BPH drugs segment is predicted to hold the largest share over the forecast period owing to its non-invasive nature, ease of administration, and widespread availability. The rising preference for hormonal therapies and anticholinergic drugs in patients with mild to moderate symptoms further boosts market growth. Combination therapies are gaining popularity for better clinical outcomes, while ongoing advancements in oral drug formulations and targeted therapies further strengthen the segment’s dominance.
Our in-depth analysis of the global benign prostatic hyperplasia treatment market includes the following segments:
|
By Treatment Type |
|
|
By Therapeutic Class |
|
|
By Distribution Channel |
|
